Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era. Chambers LM, Eskander RN, O'Malley DM. Ann Oncol 2025;36:244-246.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chambers LM, Eskander RN, O'Malley DM. Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era. Ann Oncol 2025;36:244-246.
PMID: 39984223